The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Ixion Biotechnology, Inc.

Ixion Biotechnology, Inc.
 PROFILE
Kidneys are at the heart of Ixion Biotechnology. The firm is researching an islet stem-cell therapy to correct diabetes; the islet peptide inhibits insulin. It is also studying how the body processes oxalates, a byproduct of oxalic acid found in some foods; faulty oxalate processing is responsible for kidney stones. Products in development include Ox-Control, a nutritional supplement to help the body process oxalates, and drug candidate IxC1, which may prevent kidney stones. The firm's technology is based on the genes of "Oxalobacter formigenes," a bacteria that can break down oxalates. Sweden-based Q-Med, which makes biologic-based cosmetic implants, owns nearly 60% of Ixion.

 COMPETITION
Alteon Inc. (ALT)
Baxter International Inc. (BAX)
SUGEN, Inc. (dossier)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 0.40
1-Yr. Sales Growth: 293.4%
Employees: 21
Revenue per employee: $19,047.62

 KEY PEOPLE
• Weaver H. Gaines
    CEO
• David C. Peck
    CFO

 CONTACT INFO
13709 Progress Blvd.
Alachua, FL 32615
US
Phone: 904-418-1428
Fax: 904-418-1583
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001